VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2021 | Open-label extension study of lecanemab in early Alzheimer’s disease

Chad Swanson, PhD, Eisai, Inc., Woodcliff Lake, NJ, discusses the open-label extension of the Phase IIb trial BAN2401-G000-201 (NCT01767311) of lecanemab (BAN2401) in patients with early Alzheimer’s disease. In this analysis, consenting subjects were re-admitted to the open-label extension after having been off lecanemab for an extended period of time. Therefore, it was possible to analyze clinical progression after treatment removal, the time course of amyloid removal by the antibody, as well as evaluate the incidence of ARIA-E. Dr Swanson comments on the main findings of the open-label study and shares his view on the potential impact of lecanemab in Alzheimer’s disease treatment. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.

Disclosures

Dr Swanson is an employee of Eisai, Inc.